Gastroenteropancreatic Neuroendocrine Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Gastroenteropancreatic Neuroendocrine Tumor also known as (whooping cough or pertussis), a respiratory infection, is caused by the gram-negative coccobacillus Gastroenteropancreatic Neuroendocrine Tumor and Bordetella parapertussis. The infection is spread through airborne droplets and is highly contagious, with a tendency to affect 100% of non-immune household contacts. Protection from vaccination may wane to 50% within 12 years of completion, and immunocompromised individuals may also contract Bordetella bronchiseptica, commonly known as "kennel cough." Risk factors for acquiring pertussis include pregnancy, epidemic exposure, lack of immunization, and close contact with an infected individual. The organism adheres to ciliated respiratory epithelial cells, causing local inflammatory changes in the mucosal lining and releasing toxins that act locally and systemically. Pertussis presents similarly to other respiratory infections but has a distinct progression through three phases and a persistent cough without fever. Infants and older adults have higher mortality and morbidity, respectively, with a 2% death rate in infants accounting for 96% of pertussis-related deaths. Most individuals with pertussis will recover, although the illness may last several months. Secondary complications such as pneumonia, seizures, and encephalopathy may occur. Secondary bacterial pneumonia is commonly caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, while viral infections include a respiratory syncytial virus, cytomegalovirus, and adenovirus may also occur.

·       Worldwide, there are over 24 million cases annually, with greater than 160,000 deaths.

Thelansis’s “Gastroenteropancreatic Neuroendocrine Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroenteropancreatic Neuroendocrine Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Gastroenteropancreatic Neuroendocrine Tumor across the 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Gastroenteropancreatic Neuroendocrine Tumor Market Forecast Patient-Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Gastroenteropancreatic Neuroendocrine Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032